Discover investment opportunities in Best Gene Editing Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Gene Editing Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Gene Editing Stocks using our Smart AI Filter.
6 stocks found for "Best Gene Editing Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
2.51 | ±100.0% | -1.1 | 0.00% | |||
1.92 | ±68.6% | -1.9 | 0.00% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
1.76 | ±100.0% | -6.9 | 0.00% | |||
1.98 | ±100.0% | -2.4 | 0.00% | |||
1.39 | ±92.0% | -3.9 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Read moreQ: What factors make CRISPR Therapeutics (CRSP) a potentially strong investment in gene editing?
A: Some investors consider CRISPR Therapeutics appealing due to its pioneering role in CRISPR-Cas9 technology, which allows precise genome editing. The company's collaborations and diverse clinical pipeline targeting sickle cell disease and beta-thalassemia may enhance its growth potential, although regulatory and development risks remain.
Q: How does Editas Medicine (EDIT) differentiate itself within the gene editing sector?
A: Editas Medicine is known for its CRISPR platform and focus on ocular diseases, such as Leber congenital amaurosis. The company's focus on genetic eye disorders differentiates it from peers, although the commercial success of such treatments is uncertain.
Q: What makes Intellia Therapeutics (NTLA) significant in the gene editing landscape?
A: Intellia Therapeutics is significant for developing in vivo CRISPR therapies, particularly NTLA-2001 for transthyretin amyloidosis. Its focus on delivering treatments directly within the body distinguishes it from ex vivo approaches and may offer broader applications.
Q: Are there any unique challenges for Beam Therapeutics (BEAM) in the gene editing market?
A: Beam Therapeutics faces unique challenges due to its novel base editing technology. While it allows precise single base changes in DNA, regulatory hurdles, intellectual property issues, and the unproven nature of this technology pose significant risks.
Q: How might Verve Therapeutics (VERV) impact cardiovascular disease treatment through gene editing?
A: Verve Therapeutics aims to transform cardiovascular disease treatment via gene editing, focusing on reducing LDL cholesterol levels. If successful, their techniques could alter disease treatment paradigms, though the early-stage status of their research presents both opportunity and risk.
Q: What role does Pluristem Therapeutics (PSTI) play in regenerative medicine alongside gene editing?
A: Pluristem Therapeutics focuses on cell therapy using placental cells, adding a regenerative angle to the gene editing industry. Its placenta-based therapies hold promise for treating inflammation and ischemic diseases, complementing gene editing advances.